BMAP-28 improves the efficacy of vancomycin in rat models of gram-positive cocci ureteral stent infection

Peptides
Fiorenza OrlandoAndrea Giacometti

Abstract

An experimental study was performed to evaluate the efficacy of BMAP-28 alone and in combination with vancomycin in animal models ureteral stent infection due to Enterococcus faecalis and Staphylococcus aureus. Study included a control group without bacterial challenge to evaluate the sterility of surgical procedure, a challenged control group that did not receive any antibiotic prophylaxis and for each bacterial strain three challenged groups that received (a) 10 mg/kg vancomycin intraperitoneally, immediately after stent implantation, (b) BMAP-28-coated ureteral stents where 0.2-cm(2) sterile ureteral stents were incubated in 1mg/l BMAP-28 solution for 30 min immediately before implantation and (c) intraperitoneal vancomycin plus BMAP-28-coated ureteral stent at the above concentrations. Experiments were performed in duplicate. Ureteral stents were explanted at day 5 following implantation and biofilm bacteria enumerated. Our data showed that rats that received intraperitoneal vancomycin showed the lowest bacterial numbers. BMAP-28 combined with vancomycin showed efficacies higher than that of each single compound. These results highlight the potential usefulness of this combination in preventing ureteral stent-associated in ...Continue Reading

References

May 21, 1999·Science·J W CostertonE P Greenberg
Aug 15, 2001·Diagnostic Microbiology and Infectious Disease·M Yassien, N Khardori
Mar 2, 2002·The Lancet Infectious Diseases·R E Hancock
Apr 5, 2002·Clinical Microbiology Reviews·Rodney M Donlan, J William Costerton
Dec 20, 2002·Biopolymers·Yechiel Shai
Mar 26, 2004·Nature Reviews. Microbiology·Luanne Hall-StoodleyPaul Stoodley
May 6, 2004·The Journal of Urology·Darren T BeikoJohn D Denstedt
Jan 13, 2006·World Journal of Urology·P TenkeE Nagy
Jul 4, 2006·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Milton BarrosHeonir Rocha
Nov 10, 2006·World Journal of Urology·B Lojanapiwat
Dec 13, 2006·Nature Biotechnology·Robert E W Hancock, Hans-Georg Sahl

❮ Previous
Next ❯

Citations

Sep 8, 2010·Journal of Microbiological Methods·Tom Coenye, Hans J Nelis
Jul 15, 2009·Nature Reviews. Urology·Ben H Chew, Dirk Lange
Jan 30, 2018·Frontiers in Microbiology·Lucia GrassiGiovanna Batoni
Mar 13, 2021·Drug Delivery and Translational Research·Aditya JosyulaLaura M Ensign

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.